Review Article

Endocrine Flawed In COVID-19 Era

Farhana Akter 1, Rahnuma Ahmad2, Mainul Haque3

Abstract

The clinical practice and social relationships have been changed since the emergence of COVID-19. It is declared a global pandemic affecting millions of people across the world. SARS-CoV-2 virus while infecting human has been noted to affect several vital organs and biological systems. This can occur directly through virus-induced damage or indirectly due to the host response after virus entry, which produce a negative impact on body systems. Human endocrine system similar fatal effect. Thereafter, the knowledge and clinical expertise about the management of the endocrine pathological consequences of COVID-19 is essential in the current pandemic situation. The need of such clinical proficiency is increasing more demanding as SARS-CoV-2 pandemic is growing towards more devastating phase. The coronavirus enters the human body by using the angiotensin converting enzyme 2 (ACE-2). Other than the pneumocytes, ACE-2 is expressed by several endocrine glands like the pancreas, pituitary gland, adrenal glands, thyroid, ovary, and testes. Diabetes has a significant impact on covid 19. Diabetes Mellitus is one of the comorbidities most frequently linked to severity and mortality resulting from COVID-19 infection. Thus, careful management that includes modification of treatment may be needed to protect from the most dangerous outcomes of the virus infection or hospitalization with COVID-19, not only for patients with a known history of diabetes but also those suffering SARS-CoV-2 induced new-onset diabetes. Those suffering from obesity are more susceptible to SARS-CoV-2 as well as to adverse effects. In order to limit the susceptibility and severity of SARS-CoV-2 infection, there needs to be adequate management of nutrition of obese and undernourished patients. Hypothalamic-pituitary axis suppression, adrenal insufficiency, thyroid dysfunction, hypocalcemia, vitamin D lack, and vertebral fractures have also been reported as frequent findings in COVID-19 infected individuals who needed to be hospitalized and often associated with fatal clinical outcomes. Prompt glucocorticoid adjustment is also required in patients with COVID-19 having adrenal insufficiency. Addressing hormonal status may limit further treatment burden for a COVID-19 infected patient.

Keywords: Endocrine; SARS-COV; ACE-2; COVID-19; Pandemic; Diabetes Mellitus; Thyroid; Adrenal; Obesity; Pancreas

Introduction

COVID-19 excessively distresses individuals with endocrine disabilities, accordingly stroking them at a higher risk for the severity of the disease and increased morbidity and mortality 1,2. In December 2019, there was an outbreak of meager cases of pneumonia of unrevealed basis of the disease from Wuhan, Hubei in China 3-6. The spread of the COVID-19 rapidly occurred to the remaining parts of the globe. Over the months that have followed, millions have been affected globally with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection that is frequently known as COVID-19 7,8. Internationally, “as of 6:30 pm CEST, 30 July 2021, there have

1. Department of Endocrinology, Chittagong Medical College, Chattogram 4203, Bangladesh. Orcid ID: https://orcid.org/0000-0002-4488-9388
2. Department of Physiology, Medical College for Women and Hospital, Dhaka, Bangladesh. Orcid ID: https://orcid.org/0000-0001-7379-0822
3. Unit of Pharmacology, Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia (National Defence University of Malaysia), Kem Perdana Sungai Besi, 57000 Kuala Lumpur, Malaysia. Orcid ID: http://orcid.org/0000-0002-6124-7993

Correspondence: Maimul Haque Unit of Pharmacology, Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia (National Defence University of Malaysia), Kem Perdana Sungai Besi, 57000 Kuala Lumpur, Malaysia. Email: runurono@gmail.com, mainul@upnm.edu.my
been 196,553,009 confirmed cases of COVID-19, including 4,200,412 deaths, reported to World Health Organization (WHO). As of 29 July 2021, a total of 3,839,816,037 vaccine doses have been administered. Coronavirus 2019 (COVID-19) pandemic is an immense tragedy in the history of medical science in this century. Although there are considerable differences in death rates were observed diverse around the globe, studies have consistently shown that comorbidities, primarily type 2 diabetes mellitus, suggestively increase fatal outcomes, including death among patients with SARS-CoV-2. Hospital admission of diabetic patients is out of proportion compared to the general population, as evidenced by higher admissions rates to hospitals among diabetes patients. A study in China revealed that patients admitted in ICU have much more comorbidities than non-ICU admitted patients. Research based on autopic evidence of COVID-19 patients reveals that the pathology of SARS-CoV-2 involves multiple endocrine glands. The endocrine glands frequently affected are the thyroid, parathyroid, pituitary gland, pancreas, adrenals, testis and sometimes parathyroid glands. Multiple pathological processes of COVID-19 include inflammation, vascular derangement, and autoimmune reactions to ensure functional impairment, even on some occasions the irreversible loss of endocrine damage.

Objectives of the Study

This paper aims to point up so far published information on COVID-19 with endocrine comorbidities. Furthermore, reiterate already prevailing data from preceding coronavirus outbursts experience for effective risk categorization and developing treatment protocol for patients with SARS-CoV-2 disease. This manuscript primarily focused on the endocrinopathic engagement of SARS-CoV-2 infection, as alteration of this system can contribute more in COVID-19 related mortality and morbidity. Extensive research regarding COVID-19 is ongoing to better understand the impact of endocrine involvement; thereby, more evidence-based management guidelines are expected to emerge shortly. We focused on being too aware of the endocrine sequelae of COVID-19, which might be overlooked during its management, might bring a new disaster. This paper will address precautionary measures and overall treatment measures of endocrine disease settings in the background of worldwide lockdown, movement control order (MCO), restrictions, regulations being levied, and suggest real-world instructions for ongoing endocrine management. This paper possibly makes a platform for further research to explore many unknowns in the endocrine field by covid 19 and to understand the pathophysiology of new-onset endocrine diseases by SARS-COV-2.

Materials and Methods

Published papers writing about endocrine changes in SARS-CoV-2 and SARS-CoV patients were incorporated. We have made a wide-ranging literature hand search for articles in PubMed and Google Scholar databases till June 2021, with the following keywords: “COVID-19”, “diabetes mellitus,” “thyroid disorders,” “adrenal insufficiency,” “Cushing’s syndrome,” “hypothalamus-pituitary axis,” “obesity” “management,” “treatment” and “guidelines” with interposition of the Boolean operator “AND.”

Covid 19 with Endocrine Pancreatic Changes and Diabetes Mellitus

Several viruses have been spotted as one of the perpetrators of developing diabetes mellitus in humans. Those viruses include Coxsackie B virus, enteroviruses, retroviruses, mumps, rubella, Epstein-Barr, cytomegalovirus, and varicella-zoster (Figure 1). Research studies have also reported that coronavirus, including COVID-19, can cause diabetes mellitus in animals and humans. Multiple research studies confirmed that the SARS-CoV-2 virus enters human lungs, pancreas, and other tissue cells through binding with the ACE-2. The expression of ACE-2 is much more robust in pancreatic endocrine tissue than exocrine tissue. The amount of cellular-level tissue destruction by SARS-CoV directly depends on the neck and neck of the countenance of tissue ACE-2. The expression of ACE-2 is much more robust in pancreatic endocrine tissue than exocrine tissue. The amount of cellular-level tissue destruction by SARS-CoV directly depends on the neck and neck of the countenance of tissue ACE-2. Thus, SARS-CoV viruses extensively whittle away pancreatic β-cells and cause of acute of diabetes mellitus, revealing a potential diabetogenic action of this virus (Figure 2).

Similarly, as pancreatic β-cells abundantly express ACE-2 receptors, the SARS-CoV-2 virus utilizes those receptors to enter β-cells and cause profound impairment of its physiology through damage, consequently worsening hyperglycemia in patients with among already diagnosed cases of diabetic
individual (Figure 2). These category patients frequently develop life-threatening outcome diabetes, for example, ketoacidosis or hyperosmolarity, and require high-dose insulin. Additionally, several patients develop diabetes mellitus due to complication COVID-19 hitherto nondiabetic has been steadily quantified. The temporary or insistent hyperglycemia among COVID-19 cases and the factual incidence and characterization of this afresh developed diabetes are to date under potential research issues. International registry hard work is continuing to assemble and evaluate those cases globally. Since pancreatic β-cells richly contain ACE-2 receptors, they thereby are injured by SARS-CoV-2 with significant hyperglycemia worsening in patients diagnosed with diabetic individuals, frequently byzantine with acute life-threatening medical emergency of diabetes known as diabetic ketoacidosis (DKA) along with high-dose insulin requirement.

An earlier study reported that hospitalized patients with mild coronavirus infection (without corticosteroid drugs) had a high-level fasting plasma glucose (FPG) than those with non-corona pneumonia. Additionally, among COVID-19 cases receiving no glucocorticoid medication, 51% of them develop diabetes mellitus with no diabetic evidence beforehand. After that, hyperglycemia remains a self-determining prognosticator for fatal-outcome including death and disease miseries among COVID-19 patients with and without a history of diabetes mellitus. A broad spectrum of the prevalence rate has been reported regarding the association of COVID-19 and non-communicable diseases (NCDs) among research reports within the country and globally. Nevertheless, the three most common NCDs [diabetes mellitus, hypertension, and cardiovascular disease (CVDs)] are frequently correlated with COVID-19.

It has been demanding to explore outstanding pathological aspects of diabetic COVID-19 infection because the number of cases is exploding. Multiple studies reported that diabetes mellitus remains the top comorbidities of COVID-19, frequently speedily deteriorates towards grave prognosis, and a 7-30% prevalence rate was observed. A self-determining correlation was observed between HbA1C and COVID-19 mortality rates among the British in type 1 and 2 diabetic individuals. Another
It is estimated that there are about 463 million diabetic adult individuals worldwide. Therefore, a notable proportion of the population is at a higher risk of suffering the adverse effects of COVID-19 infection. Although the pathophysiology for this higher risk has not been determined entirely, factors that may be responsible include predisposition to infection, increased inflammation, and deterioration of co-morbidities.

There can be an increase in the release of inflammatory mediators, including lipopolysaccharide, inflammatory cytokines, and chemokines like TNFα, IL-1β, IL-6, IL-8, IL-17, and toxic metabolites in the blood of those infected with SARS-CoV-2 virus. Modulation of natural killer cell activity modulation and formation of IFNγ can lead to increased permeability of the vasculature and/or interstitium for inflammatory mediators. There is also increased production of ROS (reactive oxygen species) in subjects infected with SARS-CoV-2. These events eventually result in fibrosis of the lung, acute lung damage, and acute respiratory distress syndrome (ARDS). ROS production and activation of the renin-angiotensin-aldosterone system (RAAS) by the virus via increased angiotensin II expression lead to insulin resistance, hyperglycemia, and damage of vascular endothelium.

These changes lead to cardiovascular events, thromboembolism, and disseminated intravascular coagulation. An increase in clotting components like fibrinogen and D-dimer have also been observed in COVID-19 infection, which eventually leads to a rise in blood viscosity and widespread damage of vascular endothelium and related cardiovascular events thromboembolism and DIC. The outcome of all these mechanisms can lead to thrombosis, pulmonary embolism, and eventually death. Biologically, individuals who have diabetes have instability in glycemic control, immune response impairment, and comorbidities like obesity also contribute to fatality due to the viral infection.

Meta-analysis has shown an 87% higher death risk in diabetic patients with COVID-19 than non-diabetic COVID-19 patients. Pre-existence of diabetes was associated with a higher risk of about twofold of suffering severe or critical COVID-19 illness and threefold rise in the risk of in-hospital mortality.

Studies revealed that patients infected with COVID-19 who had no other comorbidities except diabetes (n = 24) had a higher risk of developing severe pneumonia. The levels of inflammation-related...
biomarkers in the serum-like C-reactive protein, IL-6, serum ferritin, and D-dimer, coagulation index were noted to be significantly higher (P < .01) in infected subjects with diabetes in comparison to non-diabetic individuals, showing that diabetic patients are more prone to inflammatory storm eventually resulting in rapid deterioration of health condition when infected with COVID-19.

The outbreak of SARS-CoV in 2003 suggests that Covid 19 can worsen glycemic control in preexisting diabetes caused by the stress of a critical illness by increased secretion of counter-regulatory hormones like catecholamine, cortisol, Glucagon, and growth hormone. Besides this, there is an expression of ACE-2 in acinar cells and within islet cells of Langerhans of the pancreas. When SARS-CoV-2 binds with ACE-2 receptor on islet cells of the pancreas, temporary inflammation occurs in the organ, causing induction of transient hyperglycemia. This transient insulin-dependent diabetes mellitus is resolved when the disease is resolved.

Direct damage of β-cell, insulin resistance induced by cytokine, hypokalemia, and drugs used to treat COVID-19 (corticosteroids, ritonavir, or lopinavir) can deteriorate the control of glucose in diabetic patients. The two-way interaction between COVID-19 and diabetes mellitus sets up a vicious cycle. Thus, diabetes mellitus must take all necessary precautions and ensure reasonable glycemic control amid the ongoing pandemic.

“Sick day rules” need to be implemented to avoid possibly placing the health of diabetic individuals in jeopardy. Type 1 diabetic patients with fever and hyperglycemia; these patients need to monitor blood glucose and ketone levels in urine more frequently and adjust basal insulin requirement or use indemnification bolus proactively to maintain euglycemia and adapt measures to maintain appropriate glycemic control. In case of doses of an oral drug, metformin is to be stopped in all subjects who are hospitalized, and the drug can be recommenced following through clinical and laboratory appraisal of renal status, and blood lactate. A recent study suggest that progress to severe COVID-19 disease may be reduced in those taking metformin. There is a potentially higher risk of developing ketoacidosis and dehydration in patients taking sodium-glucose cotransporter-2 inhibitors (SGLT-2i), and thus this treatment should be halted. Since the protective effect of DPP4i and statins has been indicated in a recent study, it may be beneficial for the patients who are already consuming such a drug to continue taking it if no specific contraindications are present. Hyperglycemia can be controlled most effectively with insulin in hospitalized highly ill patients and is also the case for COVID-19 infection. Subcutaneous bolus basal regimen preferred for patients with persistently high blood glucose levels, and critical patient in ICU setting should be treated with intravenous insulin infusion. Insulins requirements are exceptionally high in individuals treated with dexamethasone and the use of insulin in the range of 1.2–1.5 units/kg.

**Covid 19 and Diabetes Mellitus in Pregnancy**

Gestational diabetes mellitus (GDM) is a frequent medical complication during pregnancy. Pregnant COVID-19 individuals might be at an augmented health threat in developing more serious disease processes when compared to non-pregnant individuals. Furthermore, there may be an amplified risk of adversative pregnancy consequences, for example, preterm birth and many more.

During an evolving pandemic with a highly infectious virus, screening oral glucose tolerance tests (OGTTs) involves high exposure risks and health service burden. These patients need to stay in hospitals and laboratories, susceptible to contracting and spreading the disease for a long time. Careful consideration needs to be given to the screening of GDM by routine use of OGTT in the context of the impact of the local pandemic, including community transmission rates. In the pandemic context with SARS-CoV-2 infection, the recently released new guidelines and recommendations by international authorities have considered some medical services to be unessential in antenatal care in an attempt to lower the risk of pregnant women contracting the virus. Some of the recommendations of the Royal College of Obstetricians and Gynecologists (RCOG) and Canada refer to screening for gestational diabetes, illustrated in Table 1.
**Covid 19 and Obesity**

Obese individuals infected with COVID-19 should be considered as a higher risk population\textsuperscript{101}. Chronic diseases like obstructive sleep apnea, diabetes mellitus, and lung surfactant dysfunction are linked to obesity, thus intensifying the risk of COVID-19 correlated with worsening the disease process\textsuperscript{102}. Management of subjects with severe obesity in intensive care is invariably challenging\textsuperscript{103}. Obesity is likely an independent risk factor for severe SARS-CoV-2 illness and needs to be investigated further\textsuperscript{104}. Association has been observed between obesity and pulmonary dysfunction, hypercoagulability, and raised risk of thrombosis, emerging as an essential factor resulting in a more severe clinical course in COVID-19 patients\textsuperscript{105}.

Various mechanisms have been suggested regarding the association between obesity and poor outcome of COVID-19\textsuperscript{106}. Higher ACE-2 expression in adipose tissue may lead to increased duration of viral exposure in obese subjects due to prolonged viral shedding, thus increasing SARS-CoV-2 infection susceptibility and disease aggravation risk\textsuperscript{107}. Chronic inflammation driven by obesity, aberration of cytokine activation, lowered adiponectin and raised leptin secretions, and innate and adaptive immune dysfunction may contribute to worsening clinical outcomes in patients with COVID-19\textsuperscript{108}.

**Covid 19 and Adrenal Insufficiency**

There has been the identification of SARS-CoV genome sequences in the cytoplasm of neurons in the hypothalamus and cerebral cortex\textsuperscript{109}. It possibly causes induction of hypophysitis or affects the hypothalamus, directly resulting in impaired hypothalamic-pituitary axis (HPA) function. Leow et al. revealed that in patients who improved from SARS-CoV, there was an occurrence of hypocortisolism. The study included SARS-CoV infected patients who had well-functioning hypothalamic–pituitary–adrenal (HPA) axis. After recovery, these patients complained of malaise, fatigue, weakness, orthostatic dizziness, lassitude, apathy, anorexia, anxiety, and depression. Three months following recovery, it was noted that 39·3\% of patients developed hypocortisolism, 83·3\% of which had central hypocortisolism as shown by low adrenocorticotropic hormone (ACTH) levels\textsuperscript{110}.

Interestingly, most of these individuals did not receive any systemic glucocorticoids during treatment for SARS; thus, the possibility of HPA axis suppression by exogenous corticosteroid use was ruled out. The hypocortisolism was resolved in 62·5\% of patients within a year with an average duration of 5·9±3·1 month since the condition developed was transient. Also, resolution of symptoms which include orthostatic hypotension, compared to the beginning of the study, was reported by these subjects\textsuperscript{110}.

Regarding cortisol dynamics, autopsy studies on patients who died from SARS-CoV-1 have found the adrenal cortical cells with degeneration and necrosis, suggesting a direct cytopathic effect. ACE receptors present in the adrenal cortical cells, cortisol dynamics are likely to be altered in patients with SARS-CoV-2\textsuperscript{110,111}.

Previously, data published so far have not considered the possibility of direct viral aggression towards the adrenal gland in healthy subjects, also has not been considered in the data published to date\textsuperscript{112}. Viral, bacterial, and fungal sepsis may cause adrenal hemorrhage, necrosis, or thrombosis with resultant acute hypoadrenalism. The possibility of venous thrombo-embolism occurring in COVID-19 infected patients and its favorable treatment by heparin in some of them have been suggested in recent findings\textsuperscript{113}. Thus, a thrombotic event at the adrenal level in COVID-19 patients has to be considered as a reason for acute adrenal insufficiency. The resulting acute adrenal insufficiency with hormone production impairment can eventually lead to shock and worsening of the possibility of reacting to severe respiratory distress. Screening for pituitary-adrenal axis function and identifying this condition in due time could allow appropriate replacement therapy to avoid severe shock\textsuperscript{111}.

Individuals having adrenal insufficiency or uncontrolled Cushing’s syndrome are at greater risk for death from a respiratory-related infection, like COVID-19, and in order to avoid complications, several vital recommendations need to be followed to avoid complications\textsuperscript{18}. Subjects with adrenal insufficiency also have a higher risk of infection, which may be complicated due to the development of an adrenal crisis; however, no evidence is currently present to suggest that these patients are more prone to develop a severe disease course\textsuperscript{114}. We emphasize the requirement for education (stringent social distancing rules, sick day rules), equipment (steroid emergency self-injection kit, sufficient glucocorticoid supplies),
and empowerment (COVID-19 guidelines, steroid emergency card) for adrenal crisis prevention. When patients suffering from primary adrenal insufficiency develop an acute COVID-19 infection, a stress dose of glucocorticoid with oral administration of 20 mg hydrocortisone every six hours can be considered. This may prevent the appearance of an adrenal crisis. There is a need to administer parenteral glucocorticoids in subjects with a worsening health condition in COVID-19. A proposed protocol includes intramuscular administration of 100 mg hydrocortisone, followed by 200 mg hydrocortisone per 24 hours through continuous intravenous infusion. However, until this can be established, 50 mg hydrocortisone boluses should be administered every 6 hours. If on fludrocortisone, the usual dose of (0.05-0.1mg/day) is continued. Serum potassium should be monitored strictly as hypokalemia has been reported in patients with COVID-19.

**COVID-19 and Gonads**

In the testes, there is ACE-2 expression at a high level; as a matter of fact, the mRNA and protein for ACE-2 expression are almost highest in the testis of the human body. ACE-2 is expressed by spermatogonia, Sertoli cells, and the Leydig cells. There needs to be a cautious interpretation of the serum testosterone levels in COVID-19 infected patients since hypothalamic-pituitary-testicular axis suppression may occur in any acute illness that is critical in nature. The biochemical manifestation of low follicle-stimulating hormone (FSH), luteinizing hormone (LH), and testosterone seems to appear in COVID-19 infection commonly. Although rare, side effects similar to symptoms of COVID-19 infection like sore throat, fever, and pain in muscle may occur in subjects with Graves’ disease receiving anti-thyroid medications, which may be due to a decrease in blood leukocyte count. A patient with COVID-19 infection can continue consuming Antithyroid drugs unless neutropenia develops. Lymphopenia seems to appear in COVID-19 infection commonly and is not considered an indication for halting Antithyroid drug treatment. An overlap of the symptoms due to neutropenia (sore throat, fever, flu-like illness, mouth ulceration) may occur due to infection with COVID-19 (new continuous cough, fever, flu-like illness). Clinically distinguishing between these two diagnoses would be difficult for both physicians and patients. Infected individuals with thyroid eye disease are incredibly vulnerable and at very high risk of severe illness from COVID-19 on therapy with steroid at the dosage that is immunosuppressive or other immunosuppressive agents like mycophenolate and susceptibility to COVID-19 and thyroid conditions is inadequate, but individuals suffering from thyroid disease are neither at a higher risk of contracting the SARS-CoV-2 virus nor experiencing its complications. However, if the prescribed thyroid medications are not instructed, uncontrolled thyroid disease may increase the risk of getting infected with the virus and developing complications. A person’s risk for infections and complications increases when receiving high-dose steroids, immunosuppressive drugs, and specific treatments. Such individuals need to maintain caution. An increased risk of COVID-19 infection has not been observed in subjects having Graves' or other autoimmune thyroid diseases.

Prescribed medications both for hypothyroidism and hyperthyroidism must be continued as instructed. The majority of thyroid cancer patients are not likely to be more prone to SARS-CoV-2 infection. However, there may be an increased risk of infection with the virus or its complications for subjects with metastatic thyroid cancer (papillary or medullary) who have lung metastases or undergo certain kinds of cancer treatment. Antithyroid drugs (ATDs) are not known to raise the risk of infection unless they cause neutropenia. Antithyroid drugs are not considered drugs that increase susceptibility to the virus or cause the development of more severe diseases. Although rare, side effects similar to symptoms of COVID-19 infection like sore throat, fever, and pain in muscle may occur in subjects with Graves’ disease receiving anti-thyroid medications, which may be due to a decrease in blood leukocyte count. A patient with COVID-19 infection can continue consuming Antithyroid drugs unless neutropenia develops. Lymphopenia seems to appear in COVID-19 infection commonly and is not considered an indication for halting Antithyroid drug treatment. An overlap of the symptoms due to neutropenia (sore throat, fever, flu-like illness, mouth ulceration) may occur due to infection with COVID-19 (new continuous cough, fever, flu-like illness). Clinically distinguishing between these two diagnoses would be difficult for both physicians and patients. Infected individuals with thyroid eye disease are incredibly vulnerable and at very high risk of severe illness from COVID-19 on therapy with steroid at the dosage that is immunosuppressive or other immunosuppressive agents like mycophenolate and susceptibility to COVID-19 and thyroid conditions is inadequate, but individuals suffering from thyroid disease are neither at a higher risk of contracting the SARS-CoV-2 virus nor experiencing its complications. However, if the prescribed thyroid medications are not instructed, uncontrolled thyroid disease may increase the risk of getting infected with the virus and developing complications. A person’s risk for infections and complications increases when receiving high-dose steroids, immunosuppressive drugs, and specific treatments. Such individuals need to maintain caution. An increased risk of COVID-19 infection has not been observed in subjects having Graves' or other autoimmune thyroid diseases.

Prescribed medications both for hypothyroidism and hyperthyroidism must be continued as instructed. The majority of thyroid cancer patients are not likely to be more prone to SARS-CoV-2 infection. However, there may be an increased risk of infection with the virus or its complications for subjects with metastatic thyroid cancer (papillary or medullary) who have lung metastases or undergo certain kinds of cancer treatment. Antithyroid drugs (ATDs) are not known to raise the risk of infection unless they cause neutropenia. Antithyroid drugs are not considered drugs that increase susceptibility to the virus or cause the development of more severe diseases. Although rare, side effects similar to symptoms of COVID-19 infection like sore throat, fever, and pain in muscle may occur in subjects with Graves’ disease receiving anti-thyroid medications, which may be due to a decrease in blood leukocyte count. A patient with COVID-19 infection can continue consuming Antithyroid drugs unless neutropenia develops. Lymphopenia seems to appear in COVID-19 infection commonly and is not considered an indication for halting Antithyroid drug treatment. An overlap of the symptoms due to neutropenia (sore throat, fever, flu-like illness, mouth ulceration) may occur due to infection with COVID-19 (new continuous cough, fever, flu-like illness). Clinically distinguishing between these two diagnoses would be difficult for both physicians and patients. Infected individuals with thyroid eye disease are incredibly vulnerable and at very high risk of severe illness from COVID-19 on therapy with steroid at the dosage that is immunosuppressive or other immunosuppressive agents like mycophenolate and susceptibility to COVID-19 and thyroid conditions is inadequate, but individuals suffering from thyroid disease are neither at a higher risk of contracting the SARS-CoV-2 virus nor experiencing its complications. However, if the prescribed thyroid medications are not instructed, uncontrolled thyroid disease may increase the risk of getting infected with the virus and developing complications. A person’s risk for infections and complications increases when receiving high-dose steroids, immunosuppressive drugs, and specific treatments. Such individuals need to maintain caution. An increased risk of COVID-19 infection has not been observed in subjects having Graves' or other autoimmune thyroid diseases.

Prescribed medications both for hypothyroidism and hyperthyroidism must be continued as instructed. The majority of thyroid cancer patients are not likely to be more prone to SARS-CoV-2 infection. However, there may be an increased risk of infection with the virus or its complications for subjects with metastatic thyroid cancer (papillary or medullary) who have lung metastases or undergo certain kinds of cancer treatment. Antithyroid drugs (ATDs) are not known to raise the risk of infection unless they cause neutropenia. Antithyroid drugs are not considered drugs that increase susceptibility to the virus or cause the development of more severe diseases. Although rare, side effects similar to symptoms of COVID-19 infection like sore throat, fever, and pain in muscle may occur in subjects with Graves’ disease receiving anti-thyroid medications, which may be due to a decrease in blood leukocyte count. A patient with COVID-19 infection can continue consuming Antithyroid drugs unless neutropenia develops. Lymphopenia seems to appear in COVID-19 infection commonly and is not considered an indication for halting Antithyroid drug treatment. An overlap of the symptoms due to neutropenia (sore throat, fever, flu-like illness, mouth ulceration) may occur due to infection with COVID-19 (new continuous cough, fever, flu-like illness). Clinically distinguishing between these two diagnoses would be difficult for both physicians and patients. Infected individuals with thyroid eye disease are incredibly vulnerable and at very high risk of severe illness from COVID-19 on therapy with steroid at the dosage that is immunosuppressive or other immunosuppressive agents like mycophenolate and susceptibility to COVID-19 and thyroid conditions is inadequate, but individuals suffering from thyroid disease are neither at a higher risk of contracting the SARS-CoV-2 virus nor experiencing its complications. However, if the prescribed thyroid medications are not instructed, uncontrolled thyroid disease may increase the risk of getting infected with the virus and developing complications. A person’s risk for infections and complications increases when receiving high-dose steroids, immunosuppressive drugs, and specific treatments. Such individuals need to maintain caution. An increased risk of COVID-19 infection has not been observed in subjects having Graves' or other autoimmune thyroid diseases.
self-isolation/shield for at least 12 weeks as per govt rule should be advised\(^ {135,138} \). All non-urgent surgery needs to be deferred \(^ {139} \). Additionally, radiiodine administration for hyperthyroidism will have to be postponed; planned, elective radiiodine treatments have already been canceled by most Trusts. Such a decision is based on the prioritization of emergency care delivery and anticipated difficulties in adhering to radiation protection guidelines during this pandemic \(^ {140} \).

In the thyroid gland, levels of expression of ACE-2 are high, which is more than in the lungs. Thyroid disorders related to COVID-19 include thyrotoxicosis, hypothyroidism, Subacute thyroiditis, and nonthyroidal illness syndrome. Moreover, a considerable change in thyroid cancer treatment plans is taking place with more teleconsultations and fewer diagnostic and therapeutical procedures \(^ {141} \). Word Health Organization has not recommended thyroid function assessment for COVID-19 in their clinical management guidelines \(^ {142} \). Nevertheless, alterations in thyroid function were already noted in some studies through the earlier coronavirus outbreak with SARS-CoV-2. In particular, serum levels of TSH, T3, and T4 in patients with SARS-CoV were reported to be significantly lower than in the control group in a study carried out by Wang et al. Positive correlation was observed between the severity of SARS and levels of T3, suggesting that more severe the disease, the lower was the level of T3 \(^ {143} \). COVID-19-related thyroid disorders observed from the analysis of the current literature are hypothyroidism, hyperthyroidism, subacute thyroiditis, sick euthyroid syndrome. Moreover, a considerable change in thyroid cancer treatment plans is taking place with more teleconsultations and fewer diagnostic and therapeutical procedures \(^ {141} \).

Word Health Organization has not recommended thyroid function assessment for COVID-19 in their clinical management guidelines \(^ {142} \). Nevertheless, alterations in thyroid function were already noted in some studies through the earlier coronavirus outbreak with SARS-CoV-2. In particular, serum levels of TSH, T3, and T4 in patients with SARS-CoV were reported to be significantly lower than in the control group in a study carried out by Wang et al. Positive correlation was observed between the severity of SARS and levels of T3, suggesting that more severe the disease, the lower was the level of T3 \(^ {143} \). COVID-19-related thyroid disorders observed from the analysis of the current literature are hypothyroidism, hyperthyroidism, subacute thyroiditis, sick euthyroid syndrome. Moreover, a considerable change in thyroid cancer treatment plans is taking place with more teleconsultations and fewer diagnostic and therapeutical procedures \(^ {141} \).

In the acute phase of SARS COV 2, increased interleukins concentrations, particularly interleukin 6, lead to thyrotoxicosis, and its prevalence correlates with the raised interleukin-6 \(^ {144,145} \). There are desiodases, thyroid hormone transport proteins disruption, and pituitary cell TSH secretion impairment resulting in abnormal thyroid functional parameters. There is a decrease in Free T3 concentration, which correlates with an increase in interleukin-6 and free T4 average or moderately decrease, and TSH normal or decrease \(^ {133,146} \). Such

Table 1: Proposed new strategies of screening and postpartum follow-up during the COVID-19 pandemic.

| RCOG | Canada | Australia |
|------|--------|-----------|
| Early | HbA1c or RPG | HbA1c or RPG | HbA1c and RPG |
| Pregnancy | HbA1c 5.9-6.4% or RPG 9–11 mmol/L | GDM if HbA1c ≥ 5.7% (39 mmol/mol) and/or RPG ≥ 11.1 mmol/L | HbA1c ≥5.9%# Initial FPG FPG<4.7mmol/L is normal FPG 4.7 – 5.0 mmol/L → OGTT GDM criteria as noted FPG>5.1mmol/L → GDM |
| Screening | | GDM Diagnosis: HbA1c first trimester ≥ 5.9% OGTT one or more • Fasting ≥ 5.1 mmol/L • 1 hour ≥ 10 mmol/L • 2 hour ≥ 8.5 mmol/L |
| 24 to 28 weeks screening | HbA1c and either FPG or RPG. HbA1c ≥ 5.7% (39 mmol/mol) or FPG≥95mg/dL (5.6 mmol/L) or RPG ≥ 162 mg/dL (9 mmol/L) Furthermore, at any occasion of in pregnancy, women with high-level glycosuria (2+ or above), increases the possibility of diabetes (symptoms – nocturia, thirst, polydipsia), or large for gestational age (LGA) / polyhydramnios on ultrasound should be apprised for GDM. | HbA1c and RPG | FPG OGTT if FPG 4.7-5.0 mmol/L |
| Post-Partum Follow up | HbA1c screening at 3–6 months OGTT delayed until safe | OGTT delayed 6 months postpartum or HbA1c 3–6 month |

RCOG: Royal College Obstetrics and Gynecology
anomalies are known as “low T3 syndrome” or “euthyroid sick syndrome” (abnormal thyroid function parameters in non-thyroidal illness). Such anomalies in thyroid function tests are transient in general and require no specific treatment.

Conclusion
The involvement of the endocrine system with COVID-19 remains largely unexplored in the ongoing fight with the pandemic. This manuscript reviews what is known about the impact of COVID-19 on the pathophysiology and management of diabetes as well as other endocrine glands, like pituitary, adrenal, thyroid, and gonadal function. The available data regarding the relationship between the endocrine system and COVID-19 are primarily factual and conjectural. These findings must be validated through large scale clinical studies. However, for future research, there is plenty of scopes provided by the current data. An area of active research that can be explored for future research is the short-term and long-term systemic effects of COVID-19 infection. Although it may sound premature, awareness about these possibilities needs to develop among the endocrinologists in clinical practice, mainly when dealing with survivors of COVID-19 infection.

Recommendation
There need to be large-scale studies regarding the interaction between the endocrine system and COVID-19 infection. There should also be more studies to explore the effects of COVID-19 on the different endocrine glands such as the thyroid, parathyroid, adrenal, pituitary gland, and glands. Post COVID-19 endocrine complications should be kept in mind. A clear guideline can be developed for the proper management of COVID-19 patients who suffer from endocrine disorders. Subjects with adrenal disorder receiving steroid therapy should be carefully monitored. We recommend that individuals with endocrine disorders continue to be monitored through telemedicine service and create awareness among patients to report if they develop COVID-19 symptoms. All diabetic individuals should strict control of blood glucose and blood pressure. These patients must always stick to the treatment regime and remain close supervision of their physicians. We also recommend that subjects with diabetes and obesity must follow the preventive and protective measures and be timely referred when COVID-19 infection suspects for proper management. Also, the blood glucose level of a non-diabetic individual admitted to the hospital with COVID-19 must be monitored. Care should be taken for giving proper nutrition to obese as well as undernourished individuals for maintaining optimum energy. The endocrinologists should develop awareness to manage COVID-19 complications in patients with endocrine disorders and/or endocrine disorders resulting as complications after COVID-19 infection.

Acknowledgment
The authors also express their sincere gratitude to Ms. Faiza Binte Mozammel, Photographer and Editor, student of the Department of BBA, Independent University Bangladesh, Bashundhara, Dhaka, Bangladesh, for her kind effort and time regarding image editing.

Consent for Publication
All authors reviewed and approved the final version and have agreed to be accountable for all aspects of the work, including any issues related to the accuracy or integrity of Financial Support and Sponsorship.

Author Contributions
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis, and interpretation, or in all these areas; took part in drafting, revising, or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted, and decided to be accountable for all aspects of the work.

Funding
This paper was not funded.

Disclosure
The authors declare that they do not have any financial involvement or affiliations with any organization, association, or entity directly or indirectly with the subject matter or materials presented in this article. This includes honoraria, expert testimony, employment, ownership of stocks or options, patents or grants received or pending, or royalties.
References

1. Shekhar S, Wurth R, Kamarlis CDC, Eisenhofer G, Barrera FJ, Hajdenberg M, Tonleu J, Hall JE, Schiffirin EL, Porter F, Stratakis CA, Hannah-Shmouni F. Endocrine Conditions and COVID-19. Horm Metab Res. 2020;52(7):471-484. doi: 10.1055/a-1172-1352.

2. Pal R, Banerjee M. COVID-19, and the endocrine system: exploring the unexplored. J Endocrinol Invest. 2020;43(7):1027-1031. doi: 10.1007/s40618-020-01276-8.

3. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhu, China: The mystery and the miracle. J Med Virol. 2020;92(4):401-402. doi:10.1002/jmv.25678

4. World Health Organization. Novel Coronavirus (2019-nCoV). Situation Report – 1. 2020. Available at https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf [Accessed July 31, 2021]

5. Zhu H, Wei L, Niu P. The novel coronavirus outbreak in Wuhan, China. Glob Health Res Policy. 2020;5:6. doi:10.1186/s41256-020-00135-6.

6. Khan MG, Yezdani U, Chakravorty A, Shukla T. Efforts and Challenges paved by India to confront of Corona Virus (COVID-19). Bangladesh Journal of Medical Science.2020;19(3):88–92. DOI:https://doi.org/10.3329/bjms.v19i0.48198

7. Lai CC, Shih TP, Ko WC, Tang HJ, Hsuue PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924.

8. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141-154. doi: 10.1038/s41579-020-00459-7.

9. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2021. Available at https://covid19.who.int/ [Accessed July 31, 2021]

10. Zoumpourlis V, Goulieimaki M, Rizos E, Bialiu S, Spanididos DA. [Comment] The COVID-19 pandemic as a scientific and social challenge in the 21st century. Mol Med Rep. 2020;22(4):3035-3048. doi: 10.3892/mmr.2020.11393.

11. Shi Q, Zhang X, Jiang F, Zhang X, Hu N, Bimu C, Feng J, Yan S, Guan Y, Xu D, He G, Chen C, Xiong X, Liu L, Li H, Tao J, Peng Z, Wang W. Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study. Diabetes Care. 2020;43(7):1382-1391. doi: 10.2337/dc20-0598.

12. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, Ou CQ, Li L, Chen PY, Sang L, Wang W, Li JF, Li CC, Ou LM, Cheng B, Xiong S, Ni ZY, Xiang J, Hu Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Cheng LL, Ye F, Li SY, Zheng JP, Zhong NF, Zhong NS, He JX; China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. doi: 10.1183/13993003.00547-2020.

13. Hartmann-Boyce J, Morris E, Goyder C, Kinton J, Perrin J, Nunan D, Mahtani K, Buse JB, Del Prato S, Ji L, Roussel R, Khunti K. Diabetes and COVID-19: Risks, Management, and Learnings From Other National Disasters. Diabetes Care. 2020;43(8):1695-1703. doi: 10.2337/dc20-1192.

14. Gianchandani R, Essedriari NH, Ang L, Iyengar J, Knotts S, Choksi P, Pop-Busui R. Managing Hyperglycemia in the COVID-19 Inflammatory Storm. Diabetes. 2020;69(10):2048-2053. doi: 10.2337/dbi20-0022.

15. Liu Y, Yang Y, Chen Y, Zhou L, Xiong Q, Xie C. The relationship between hyperglycemia and the infection of COVID-19 in diabetic patients: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2020;99(36):e21806. doi: 10.1097/MD.0000000000021806.

16. Riddle MC, Buse JB, Franks PW, Knowler WC, Ratner RE, Selvin E, Wexler DI, Kahn SE. COVID-19 in People With Diabetes: Urgently Needed Lessons From Early Reports. Diabetes Care. 2020;43(7):1378-1381. doi: 10.2337/dc20-0024.

17. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069. doi: 10.1001/jama.2020.1585.

18. Parolin M, Parisotto M, Zanchetta F, Santorato P, De Menis E. Coronaviruses and Endocrine System: a Systematic Review on Evidences and Shadows. Endocr Metab Immune Disord Drug Targets. 2020. doi: 10.2174/187153032066620090512332.

19.isco G, De Tullio A, Stragapede A, Solimando A, Albanese F, Capobianco M, Giagulli V A, Guastamacchia D, Bystryn JC, Chen SY, Zheng JP, Zhang NF, Zhong NS, He JX; China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. doi: 10.1183/13993003.00547-2020.

20. Lisco G, De Tullio A, Stragapede A, Solimando A, Albanese F, Capobianco M, Giagulli V A, Guastamacchia D, Bystryn JC, Chen SY, Zheng JP, Zhang NF, Zhong NS, He JX; China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. doi: 10.1183/13993003.00547-2020.
Karnani N, Leow MKS. COVID-19 endocrinopathy with hindsight from SARS. Am J Physiol Endocrinol Metab. 2021;320(1):E139-E150. doi: 10.1152/ajpendo.00480.2020.

20. Szopa TM, Titchener PA, Portwood ND, Taylor KW. Diabetes mellitus due to viruses—some recent developments. Diabetologia. 1993;36(8):687-95. doi: 10.1007/BF00401138. PMID: 8405735.

21. Paschou SA, Papadopoulos-Marketou N, Chrousos GP, Kanaka-Gantenbein C. On type 1 diabetes mellitus pathogenesis. Endocr Connect. 2018;7(1): R38-R46. doi: 10.1530/EC-17-0347.

22. Jaeckel E, Manns M, Von Herrath M. Viruses and diabetes. Ann NY Acad Sci. 2002; 958:7-25. doi: 10.1111/

23. Sevilla N, Homann D, von Herrath M, Rodriguez F, Harkins S, Whitton JL, Oldstone MB. Virus-induced diabetes in a transgenic model: role of cross-reacting viruses and quantitation of effector T cells needed to cause disease. J Virol. 2000;74(7):3284-92. doi: 10.1128/jvi.74.7.3284-3292.2000.

24. Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH, Mingrone G, Boehm B, Cooper ME, Chai Z, Del Prato S, Ji L, Hopkins D, Herman WH, Khunti K, Mbanya JC, Renard E. New-Onset Diabetes in Covid-19. J Hum Hypertens. 2020;34(8):789-790. doi: 10.1016/j.jhyp.2020.08.003.

25. Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021;17(1):11-30. doi: 10.1038/s41574-020-00435-4.

26. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273. doi: 10.1038/s41586-020-1217-7.

27. Beyerstedt S, Casaro EB, Rangel ÉB. COVID-19: angiotensin-converting enzyme 2 (ACE-2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis. 2021;40(5):905-919. doi:10.1007/s10096-020-04138-6.

28. Bhalla V, Blish CA, South AM. A historical perspective on ACE-2 in the COVID-19 era. J Hum Hypertens. 2020;1-5. doi: 10.1038/s41371-020-00459-3.

29. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol. 2020;94(7):e00127-20. doi: 10.1128/JVI.00127-20.

30. Astuti I, Ysrafil. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabeties Metab Syndr. 2020;14(4):407-412. doi: 10.1016/j.dsx.2020.04.020.

31. Salamanna F, Maglio M, Landini MP, Fini M. Body Localization of ACE-2: On the Trail of the Keyhole of SARS-CoV-2. Front Med (Lausanne). 2020;7:594495. doi: 10.3389/fmed.2020.594495.

32. Fignani D, Licata G, Brusco N, Nigi L, Grieco GE, Marselli L, Overbergh L, Gyssemans C, Colli ML, Marchetti P, Mathieu C, Eizirik DL, Sebastiani G, Dotta F. SARS-CoV-2 Receptor Angiotensin I-converting Enzyme Type 2 (ACE-2) Is Expressed in Human Pancreatic β-Cells and in the Human Pancreas Microvasculature. Front Endocrinol (Lausanne). 2020;11:596898. doi: 10.3389/fendo.2020.596898.

33. Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010;47(3):193-9. doi: 10.1007/s00592-009-0109-4.

34. Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, Sun GZ, Yang GR, Zhang XL, Wang L, Xu X, Xu XP, Chan JC. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006;23(6):623-8. doi: 10.1111/j.1464-5491.2006.01861.x.

35. Steenblock C, Richter S, Berger I, Barovic M, Schmid J, Schubert U, Jarzewska N, von Mässenhausen A, Linkermann A, Schürmann A, Pablik J, Dienesmann T, Evert K, Rodionov RN, Semenova NY, Zinserling VA, Gainetdinov RR, Baretton G, Lindemann D, Solimena M, Ludwig B, Bornstein SR. Viral infiltration of pancreatic islets in patients with COVID-19. Nat Commun. 2021;12(1):3534. doi: 10.1038/s41467-021-23886-3.

36. Al-Kuraishy HM, Al-Gareeb AI, Alblihed M, Guerreiro SG, Cruz-Martins N, Batlha GE. COVID-19 in Relation to Hyperglycemia and Diabetes Mellitus. Front Cardiiovasc Med. 2021;8:644095. doi: 10.3389/fcvm.2021.644095.

37. Liao YH, Zheng JQ, Zheng CM, Lu KC, Chao YC. Novel Molecular Evidence Related to COVID-19 in Patients with Diabetes Mellitus. J Clin Med. 2020;9(12):3962. doi: 10.3390/jcm9123962.

38. Eskandarani RM, Sawan S. Diabetic Ketoacidosis on Hospitalization with COVID-19 in a Previously Nondiabetic Patient: A Review of Pathophysiology. Clin Med Insights Endocrinol Diabetes. 2020;13:1179551420984125. doi: 10.1177/1179551420984125.

39. Akter F, Mannan A, Mehedi HMM, Rob MA, Ahmed S, Salauddin A, Hossain MS, Hasan MM. Clinical characteristics and short-term outcomes after recovery from COVID-19 in patients with and without diabetes in Bangladesh. Diabetes Metab Syndr. 2020;14(6):2031-2038. doi: 10.1016/j.dsx.2020.10.016.

40. Puig-Domingo M, Marazuela M, Yildiz BO, Giustina A. COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology. Endocrine. 2021;72(2):301-316. doi: 10.1007/s12020-021-02734-w.
2 diabetes with COVID-19-related mortality in England: a whole-population study. *Lancet Diabetes Endocrinol.* 2020;8(10):813-822. doi: 10.1016/S2213-8587(20)30272-2.

53. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, MacKenna B, Tomlinson L, Douglas IJ, Rentsch CT, Mathur R, Wong AYS, Grieve R, Harrison D, Forbes H, Schultz A, Croker R, Parry J, Hester F, Harper S, Evans SJW, Smeeth L, Goldacre B. Factors associated with COVID-19-related death using OpenSAFELY. *Nature.* 2020;584(7821):430-436. doi: 10.1038/s41586-020-2521-4.

54. Muniangi-Muhiutu H, Akalestou E, Salem V, Misra S, Oliver NS, Rutter GA. Covid-19 and Diabetes: A Complex Bidirectional Relationship. *Front Endocrinol (Lausanne).* 2020;11:582936. doi: 10.3389/fendo.2020.582936.

55. Shahzad F, Nasim MT. COVID-19: A natural phenomena or laboratory-based origin? *Bangladesh Journal of Medical Science.* 2020;19: S 85–S 87.DOI: https://doi.org/10.3329/bjms.v19i0.48197

56. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzzuira K, Greenough TC, Choe H, Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature.* 2003;426(6965):450-4. doi: 10.1038/nature02145.

57. Khan S, Rafat D, Khan AU, Rahman SZ, Farhat N. Application of saliva in COVID-19 diagnosis: Challenges and opportunities. *Bangladesh Journal of Medical Science.* 2020;20(4):697-9. DOI: https://doi.org/10.3329/bjms.v20i4.54122

58. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive Care Med.* 2020;46(4):586-590. doi: 10.1007/s00134-020-05985-9.

59. Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. *Cell Metab.* 2020;31(6):1068-77.e3. doi: 10.1016/j.cmet.2020.04.021.

60. Holman N, Knighton P, Kar P, O’Keefe J, Curley M, Weaver A, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. *Lancet Diabetes Endocrinol.* 2020;8(10):823–833. doi: 10.1016/s2213-8587(20)30271-0.

61. Fleming N, Sacks LJ, Pham CT, Neoh SL, Ekinci EI. An overview of COVID-19 in people with diabetes: Pathophysiology and considerations in the inpatient setting. *Diabet Med.* 2021;38(3):e14509. doi: 10.1111/dme.14509.

62. International Diabetes Federation. Diabetes facts & figures. 2020. Available at https://idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html [Accessed August 1, 2021]

63. Corona G, Pizzocaro A, Vena W, Rastrelli G, Semeraro
F, Isidori AM, Pivonello R, Salonia A, Sforza A, Maggi M. Diabetes is a most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis. *Rev Endocr Metab Disord.* 2021;22(2):275-296. doi: 10.1007/s11154-021-09630-8.

64. Nansen A, Christensen JP, Marker O, Thomsen AR. Sensitization to lipopolysaccharide in mice with asymptomatic viral infection: role of T cell-dependent production of interferon-gamma. *J. Infect. Dis.* 1997;176:151–157. doi: 10.1086/514017.

65. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.

66. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, Zhang X, Zhang M, Wu S, Song J, Chen T, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest.* 2020;130(5):2620-2629. doi: 10.1172/JCI137244.

67. Darif D, Hammi I, Kihel A, El Idrissi Saik I, Guessous F, Akarid K. The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong? *Microb Pathog.* 2021;153:104799. doi: 10.1016/j.micpath.2021.104799.

68. Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. *J Thorac Oncol.* 2020;15(5):700-704. doi: 10.1016/j.jtho.2020.02.010.

69. Imai Y, Kuba K, Neely GG, Yaghoubian-Malhami R, Perkmann T, van Loo G, Ermolaeva M, Veldhuizen R, Leung YH, Wang H, Liu H, Sun Y, Pasparakis M, Kopf M, Mech C, Bavari S, Peiris JS, Slutsky AS, Akira S, Hultqvist C, Bavari S, Peiris JS, Slutsky AS, Akira S, Hultqvist J. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. *Cell.* 2008;133(2):235-49. doi: 10.1016/j.cell.2008.02.043.

70. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. *Lancet Respir Med.* 2020;8(8):807-815. doi: 10.1016/S2213-2600(20)30225-3.

71. John, AE, Joseph, C, Jenkins, G, Tatler, AL. COVID-19 and pulmonary fibrosis: Apotential role for lung epithelial cellsand fibroblasts. *Immunol Rev.* 2021;302:228–240. doi:https://doi.org/10.1111/imr.12977

72. Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. *Cardiovasc Diabetol.* 2018;17(1):121. doi: 10.1186/s12933-018-0763-3.

73. Nogami K, Muraki I, Imano H, Iso H. Risk of disseminated intravascular coagulation in patients with type 2 diabetes mellitus: retrospective cohort study. *BMJ Open.* 2017;7(1):e013894. doi: 10.1136/bmjopen-2016-013894.

74. Kohansal Vajari M, Shirin M, Pourbagheri-Sigaroodi A, Akbari ME, Abolghasemi H, Bashash D. COVID-19-related coagulopathy: A review of pathophysiology and pharmaceutical management. *Cell Biol Int.* 2021;10.1002/cbin.11623. doi: 10.1002/cbin.11623.

75. Eljilany I, Elzouki AN. D-Dimer, Fibrinogen, and IL-6 in COVID-19 Patients with Suspected Venous Thromboembolism: A Narrative Review. *Vasc Health Risk Manag.* 2020;16:455-462. doi: 10.2147/VHRM.S289062.

76. Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. *E Clinical Medicine.* 2020;29:100639. doi: 10.1016/j.eclinm.2020.100639.

77. Gupta R, Hussain A, Misra A. Diabetes and COVID-19: evidence, current status, and unanswered research questions. *Eur J Clin Nutr.* 2020;74(6):864-870. doi: 10.1038/s41430-020-0652-1.

78. Kandil H, Ibrahim AE, Afifi N, Arafia A. Diabetes and Risk of COVID-19 Mortality: A Systematic Review and Meta-Analysis. *Infect Dis Clin Prat (Baltim Md).* 2021;29(3):e195-e197. doi: 10.1097/IPC.0000000000000992.

79. Mantovani A, Byrne CD, Zheng MH, Targher G. Diabetes as a risk factor for greater COVID-19 severity and inhospital death: A meta-analysis of observational studies. *Nutr Metab Cardiovasc Dis.* 2020;30(8):1236-1248. doi: 10.1016/j.numecd.2020.05.014.

80. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, Qin R, Wang H, Shen Y, Du K, Zhao L, Fan H, Luo S, Hu D. Diabetes is a risk factor for the progression and prognosis of COVID-19. *Diabetes Metab Res Rev.* 2020;e3319. doi: 10.1002/dmr.3319.

81. Mirzaei F, Khodadadi I, Vafaei SA, Abbasi-Oshaghi E, Tayebinia H, Farahani F. Importance of hyperglycemia in COVID-19 intensive-care patients: Mechanism and treatment strategy. *Prim Care Diabetes.* 2021;15(3):409-416. doi: 10.1016/j.pcd.2021.01.002.

82. Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, Hou C, Wang H, Liu J, Yang D, Xu Y, Cao Z, Gao Z. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. *Crit Care.* 2020;24(1):422. doi: 10.1186/s13054-020-03120-0.

83. Pal R, Bhadada SK. COVID-19 and diabetes mellitus: An unholy interaction of two pandemics. *Diabetes Metab Syndr.* 2020;14(4):513-517. doi: 10.1016/j.dsx.2020.04.049.

84. NHS London Clinical Networks. Sick day rules: how to manage Type 2 diabetes if you become unwell with coronavirus and what to do with your medication. Updated Apr 6, 2020. Available at https://www.england.nhs.uk/london/wp-content/uploads/sites/8/2020/04/ -Covid-
85. Puig-Domingo M, Marazuela M, Giustina A. COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. Endocrine. 2020;68(1):2-5. doi: 10.1007/s12020-020-02294-5.

86. Zangiabadian M, Nejadghaderi SA, Zahmatkesh MM, Hajikhani B, Miraaeid M, Nasiri MJ. The Efficacy and Potential Mechanisms of Metformin in the Treatment of COVID-19 in the Diabetics: A Systematic Review. Front Endocrinol (Lausanne). 2021;12:645194. doi: 10.3389/fendo.2021.645194.

87. Bramante CT, Ingraham NE, Murray TA, Marmor S, Hovertsen S, Gronski J, McNeil C, Feng R, Guzman G, Abdelwahab N, King S, Tamariz L, Meehan T, Pendleton KM, Benson B, Vojta D, Tignanelli CJ. Metformin and risk of mortality in patients hospitalized with COVID-19: a retrospective cohort analysis. Lancet Healthy Longev. 2021;2(1):c34-e41. doi: 10.1016/S2666-7568(20)30033-7.

88. Cheng X, Liu YM, Li H, Zhang X, Lei F, Qin JJ et al. Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020;32(4):537-547. e3. doi: 10.1016/j.cmet.2020.08.013.

89. Vitale RJ, Valtis YK, McDonnell ME, Palermo NE, Fisher NDL. Euglycemic Diabetic Ketoacidosis With COVID-19 Infection in Patients With Type 2 Diabetes Taking SGLT2 Inhibitors. AACE Clin Case Rep. 2021;7(1):10-13. doi: 10.1016/j.jaace.2020.11.019.

90. McDonnell ME, Umpierrez GE. Insulin therapy for the management of hyperglycemia in hospitalized patients. Endocrinol Metab Clin North Am. 2012;41(1):175-201. doi: 10.1016/j.ecl.2012.01.001.

91. Fayfman M, Pasquel FJ, Umpierrez GE. Management of Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. Med Clin North Am. 2017;101(3):587-606. doi: 10.1016/j.mcna.2016.12.011.

92. Centers for Disease Control and Prevention. Considerations for Inpatient Obstetric Healthcare Settings National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. 2020. Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/inpatient-obstetric-healthcare-guidance.html [Accessed August 1, 2021]

93. Royal College of Obstetricians and Gynaecologists. Guidance for maternal medicine services in the evolving coronavirus (COVID-19) pandemic. Information for healthcare professionals. Version 2.4: Available at https://www.rcog.org.uk/globalassets/documents/guidelines/2020-07-10-guidance-for-maternal-medicine.pdf [Accessed August 1, 2021]

94. Van-de-l’Isle Y, Steer PJ, Watt Coote I, Cauldwell M. Impact of changes to national UK Guidance on testing for gestational diabetes screening during a pandemic: a single-center observational study. BJOG. 2021;128(5):917-920. doi: 10.1111/1471-0528.16482.

95. McIntyre HD, Gibbons KS, Ma RCW, Tam WH, Sacks DA, Lowe J, Madsen LR, Catalano PM. Testing for gestational diabetes during the COVID-19 pandemic. An evaluation of proposed protocols for the United Kingdom, Canada, and Australia. Diabetes Res Clin Pract. 2020;167:108353. doi: 10.1016/j.diabres.2020.108353.

96. Australian Diabetes Society. Diagnostic Testing for Gestational diabetes mellitus (GDM) during the COVID-19 pandemic: Academic and postnatal testing advice. Queensland Clinical Guidelines. Queensland Government. 2020. Available at https://www.adips.org/documents/COVID19-WITHOLDGUIDELINES0704201150ADIPSA-DSADEADAupdated.pdf [Accessed August 1, 2021]

97. Yamamoto JM, Donovan LE, Feig DS, Berger H. Urgent Update – Temporary Alternative Screening Strategy for Gestational Diabetes Screening during the COVID-19 Pandemic. A Joint Consensus Statement from the Diabetes Canada Clinical Practice Guidelines Steering Committee* and the Society of Obstetricians and Gynecologists of Canada. Mount Sinai Hospital, 60 Murray St. #5027, Toronto, Ontario, Canada. 2020. Available at https://www.sogc.org/common/Uploaded%20files/GDM-COVID-19%20temporary%20screening%20guidelines%20-%2020200402%20Agreed%20Final.pdf [Accessed August 1, 2021]

98. Katsoulis M, Pasea L, Lai AG, Dobson RJB, Denaxas S, Hemingway H, Banerjee A. Obesity during the COVID-19 pandemic: both cause of high risk and potential effect of lockdown? A population-based electronic health record study. Public Health. 2021;191:41-47. doi: 10.1016/j.puhe.2020.12.003

99. Agarwal S, Agarwal SK. Endocrine changes in SARS-CoV-2 patients and lessons from SARS-CoV. Postgraduate Medical Journal 2020;96:412-416.

100. Bajwa SJ, Sehgal V, Bajwa SK. Clinical and critical care concerns in severely ill obese patients. Indian J Endocrinol Metab. 2012;16(5):740-8. doi: 10.4103/2230-8210.100667.

101. Ryan DH, Ravussin E, Heymsfield S. COVID 19 and the obesity population to COVID-19. Int J Obes (Silver Spring). 2020;28(5):847. doi: 10.1002/oby.22808.

102. Kimura T, Namkoong H. Susceptibility of the obese to COVID-19: concerns in severely ill obese patients. Front Immunol. 2020;11:1356. doi: 10.3389/fimmu.2020.581356.

103. Moriconi D, Masi S, Rebelos E, Virdis A, Manca ML, De
Marco S, Taddei S, Nannipieri M. Obesity prolongs the hospital stay in patients affected by COVID-19 and may impact on SARS-COV-2 shedding. *Obes Res Clin Pract.* 2020;14(3):205-209. doi: 10.1016/j.orcp.2020.05.009.

106. Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, Zou W, Zhan J, Wang S, Xie Z, Zhuang H, Wu B, Zhong H, Shao H, Fang W, Gao D, Pei F, Li X, He Z, Xu D, Shi X, Anderson VM, Leong AS. Multiple organ infection and the pathogenesis of SARS. *J Exp Med.* 2005;202(3):415-24. doi: 10.1084/jem.20050828.

107. Leow MK, Kwek DS, Ng AW, Ong KC, Kaw GJ, Lee LS. Hypocortisolism in survivors of severe acute respiratory syndrome (SARS). *Clin Endocrinol (Oxf).* 2005;63(2):197-202. doi: 10.1111/j.1365-2265.2005.02325.x.

108. Bellastella G, Maiorino MI, Esposito K. Endocrine complications of COVID-19: what happens to the thyroid and adrenal glands? *J Endocrinol Invest.* 2020;43(8):1169-1170. doi: 10.1007/s40618-020-01311-8.

109. Isidori AM, Arnaldi G, Boscaro M, Falorni A, Giordano C, Giordano R, Pivonello R, Pofi R, Hasenmayer V, Venneri MA, Shardenella E, Simeoli C, Scaroni C, Lenzi A. COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency. *J Endocrinol Invest.* 2020;43(8):1141-1147. doi: 10.1007/s40618-020-01266-w.

110. Porfidia A, Pola R. Venous thromboembolism in COVID-19 patients. *J Thromb Haemost.* 2020;18(6):1516-1517. doi: 10.1111/jth.14842.

111. Schaffer R. Treating endocrine conditions in the age of COVID-19: What experts have learned. Healio. Updated Jun 10, 2020. Available at [https://www.healio.com/news/endocrinology/20200610/treating-endocrine-conditions-in-the-age-of-covid19-what-experts-have-learned](https://www.healio.com/news/endocrinology/20200610/treating-endocrine-conditions-in-the-age-of-covid19-what-experts-have-learned) [Accessed Aug 10, 2021]

112. Arlt W, Baldeweg SE, Pearce SHS, Simpson HL. Endocrinology in the Time of COVID-19: Management of adrenal insufficiency. *Eur J Endocrinol.* 2020;183(1):G25-G32. doi: 10.1530/EJE-20-0361.

113. Podder CS, Chowdhury N, Haque WMM. Management of a case of COVID-19 with adrenal crisis at a semi-urban primary healthcare center. *BIRDEM Med J.* 2020;10: S122- S126.

114. Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab.* 2016;101(2):364-89. doi: 10.1210/jc.2015-1710.

115. Almeida MQ, Mendonca BB. Adrenal Insufficiency and Glucocorticoid Use During the COVID-19 Pandemic. *Clinics (Sao Paulo).* 2020;75:e2022. doi: 10.6061/clinics2020/e2022

116. Pal R, Bhadada SK. Managing common endocrine disorders amid COVID-19 pandemic. *Diabetes Metab Syndr.* 2020;14(5):767-771. doi: 10.1016/j.dsx.2020.05.050.

117. Fan C, Lu W, Li K, Ding Y, Wang J. ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Infection in COVID-19 Patients. *Front Med (Lausanne).* 2021; 7:563893. doi: 10.3389/fmed.2020.563893.

118. Wang Z, Xu X. scRNA-seq Profiling of Human Testes Reveals the Presence of the ACE2 Receptor, A Target for SARS-CoV-2 Infection in Spermatogonia, Leydig and Sertoli Cells. *Cells.* 2020;9(4):920. doi: 10.3390/cells9040920.

119. Selvaraj K, Ravichandran S, Krishnan S, Radhakrishnan RK, Manickam N, Kandasamy M. Testicular Atrophy and Hypothalamic Pathology in COVID-19: Possibility of the Incidence of Male Infertility and HPG Axis Abnormalities. *Reprod Sci.* 2021:1–8. doi: 10.1007/s43032-020-00441-x.

120. Dhindsa S, Zhang N, McPhaul MJ, Wu Z, Ghahtal AK, Erlich EC, Mani K, Randolph GJ, Edwards JR, Mudd PA, Diwan A. Association of Circulating Sex Hormones With Inflammation and Disease Severity in Patients With COVID-19. *JAMA Netw Open.* 2021;4(5):e2111398. doi: 10.1001/jamanetworkopen.2021.11398.

121. Selek A, Giuçlü M, Bolu SE. COVID-19 pandemic: what about the gonads? *Hormones (Athens).* 2021;20(2):259-268. doi: 10.1007/s42000-021-00277-3.

122. Ma L, Xie W, Li D, Shi L, Ye G, Mao Y et al. Evaluation of sex-related hormones and semen characteristics in reproductive-aged male COVID-19 patients. *J Med Virol.* 2021;93(1):456-462. doi: 10.1002/jmv.26259.

123. Hashem NM, Abdelnour SA, Alhimaidi AR, Swelum AA. Potential impacts of COVID-19 on reproductive health: Scientific findings and social dimension. *Saudi J Biol Sci.* 2021;28(3):1702-1712. doi: 10.1016/j.sjbs.2020.12.012.

124. AACE.AACE Position Statement: Coronavirus (COVID-19) and People with Thyroid Disease.Updated Apr 15, 2020. Available at [https://pro.aace.com/recent-news-and-updates/aace-position-statement-coronavirus-covid-19-and-people-thyroid-disease](https://pro.aace.com/recent-news-and-updates/aace-position-statement-coronavirus-covid-19-and-people-thyroid-disease) [Accessed Aug 10, 2021]

125. Dworakowska D, Grossman AB. Thyroid disease in the time of COVID-19. *Endocrine.* 2020; 68(3):471-474. doi: 10.1007/s12020-020-02364-8.

126. Chen W, Tian Y, Li Z, Zhu J, Wei T, Lei J. Potential Interaction Between SARS-CoV-2 and Thyroid: A Review. *Endocrinology.* 2021;162(3):bqab004. doi: 10.1210/endcr/bqab004.

127. Albert Health Services.COVID-19 Scientific Advisory Group Rapid Evidence Report.2020. Available at [https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-sag-immunosuppression-and-covid-19-risk-rapid-review.pdf](https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-sag-immunosuppression-and-covid-19-risk-rapid-review.pdf) [Accessed Aug 10, 2021]

128. Ruggeri RM, Campenni A, Deandreis D, Siracusa M, Tozzoli R, Petranović Ovčariček P, Giovanella L. SARS-CoV-2-related immune-inflammatory thyroid disorders: facts and perspectives. *Expert Rev Clin Immunol.* 2021:1-23. doi: 10.1080/1744666X.2021.1932467.
129. Murtas R, Andreano A, Gervasi F, Guido D, Consolazio D, Tunesi S, et al. association between autoimmune diseases and COVID-19 as assessed in both a test-negative case-control and population case-control design. *Auto Immun Highlights*. 2020;**11**(1):15. doi: 10.1186/s13317-020-00141-1.

130. Caron P. Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management. *Ann Endocrinol (Paris)*. 2020;**81**(5):507-510. doi: 10.1016/j.ando.2020.09.001.

131. Malik J, Malik A, Javaid M, Zahid T, Ishaq U, Shoaib M. Thyroid function analysis in COVID-19: A retrospective study from a single center. *PLoS One*. 2021;**16**(3):e0249421. doi: 10.1371/journal.pone.0249421.

132. Boelaert K, Visser WE, Taylor PN, Moran C, Léger J, Persani L. ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of hyperthyroidism and hypothyroidism. *Eur J Endocrinol*. 2020;**183**(1): G33-G39. doi: 10.1530/EJE-20-0445.

133. Vicente N, Cardoso L, Barros L, Carrilho F. Antithyroid Drug-Induced Agranulocytosis: State of the Art on Diagnosis and Management. *Drugs R D*. 2017;**17**(1):91-96. doi: 10.1007/s40268-017-0172-1.

134. British Thyroid Association. BTA/SFE statement regarding issues specific to thyroid dysfunction during the COVID-19 pandemic. Updated Mar 25, 2020. Available at [https://www.british-thyroid-association.org/sandbox/bta2016/management-of-thyroid-dysfunction-during-covid-19_final.pdf](https://www.british-thyroid-association.org/sandbox/bta2016/management-of-thyroid-dysfunction-during-covid-19_final.pdf) [Accessed Aug 10, 2021]

135. British Thyroid Foundation. Thyroid disease and coronavirus (Covid-19). Updated Mar 5, 2020. Available at [https://www.btf-thyroid.org/news/thyroid-disease-and-coronavirus-covid-19](https://www.btf-thyroid.org/news/thyroid-disease-and-coronavirus-covid-19) [Accessed Aug 10, 2021]

136. Baud G, Brunaud L, Lifaitel JC, Tresallet C, Sebag F, Bizard JP, et al. Endocrine surgery during and after the COVID-19 epidemic: Expert guidelines from AFCE. *J Visc Surg*. 2020;**157**(3S1): S43-S49. doi: 10.1016/j.jviscsurg.2020.04.018.

137. Chen M, Zhou W, Xu W. Thyroid Function Analysis in 50 Patients with COVID-19: A Retrospective Study. *Thyroid*. 2021;**31**(1):8-11. doi: 10.1089/thy.2020.0363.

138. Scappaticcio L, Pitoia F, Esposito K, Piccardo A, Trimboli P. Impact of COVID-19 on the thyroid gland: an update. *Rev Endocr Metab Disord*. 2020;1–13. doi: 10.1007/s11154-020-09615-z.

139. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: Interim guidance. 2020. Available at [https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf](https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf) [Accessed August 1, 2021]

140. Wei L, Sun S, Xu CH, Zhang J, Xu Y, Zhu H, Peh SC, Korteweg C, McNutt MA, Gu J. Pathology of the thyroid in severe acute respiratory syndrome. *Hum Pathol*. 2007;**38**(1):95-102. doi: 10.1016/j.humpath.2006.06.011.

141. Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodriguez L. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. *Cytokine Growth Factor Rev*. 2020;**54**:62-75. doi: 10.1016/j.cytogfr.2020.06.001.

142. Lania A, Sandri MT, Cellini M, Mirani M, Lavezzi E, Mazziotti G. Thyrotoxicosis in patients with COVID-19: the THYRCOV study. *Eur J Endocrinol*. 2020;**183**(4):381-387. doi: 10.1530/EJE-20-0335.

143. Wang W, Ye YX, Yao H. Evaluation and observation of serum thyroid hormone and parathyroid hormone in patients with severe acute respiratory syndrome. *J Chin Antituberculous Assoc.*. 2003;**25**:232–234.

144. Fliers E, Bianco AC, Langouche L, Boelen A. Thyroid function in critically ill patients. *Lancet Diabetes Endocrinol*. 2015;3:816–825.